hepat
b
viru
hbv
import
account
infecti
hepat
interferon
ifn
remain
one
best
treatment
option
activ
type
ifn
signal
pathway
lead
express
ifnstimul
gene
isg
play
import
role
antivir
immunomodulatori
respons
hbv
hepat
c
viru
hcv
infect
previou
studi
indic
conjug
isgyl
exploit
hcv
benefit
replic
persist
infect
studi
design
assess
role
isgyl
hbv
infect
vitro
level
isgyl
upregul
plasmid
transfect
cell
decreas
isgyl
achiev
sirna
target
activ
enzym
isgyl
overexpress
subsequ
isgyl
significantli
increas
level
hbv
dna
cultur
supernat
although
intracellular
viral
replic
remain
unaffect
silenc
decreas
isgyl
achiev
abrog
isgylationmedi
promot
effect
data
indic
overexpress
stimul
hbv
product
isgylationdepend
manner
identif
protein
either
hbv
viral
host
protein
may
reveal
promis
candid
antivir
drug
develop
hepat
b
viru
hbv
major
caus
liver
diseas
approxim
million
peopl
infect
world
one
million
death
caus
liver
cirrhosi
primari
hepatocellular
carcinoma
hcc
follow
chronic
hbv
infect
make
seriou
public
health
problem
unfortun
current
type
interferon
ifn
base
antivir
therapi
suboptim
antivir
effect
indic
substanti
drug
resist
mechan
explor
order
develop
effect
treatment
strategi
ifnstimul
gene
isg
induc
type
ifn
isg
play
differ
role
direct
indirect
antivir
activ
cytoskelet
remodel
apoptosi
induct
posttranscript
posttransl
regul
viral
molecul
detect
signal
pathway
modul
structur
homolog
ubiquitin
one
abund
ifninduc
isg
similar
ubiquitin
conjug
target
protein
process
call
isgyl
catalyz
activ
conjug
ligas
ubiquitinlik
specif
proteas
specif
deconjug
enzym
remov
target
antivir
activ
isgyl
verifi
lot
studi
investig
viru
host
interact
either
overexpress
knockdown
cell
defici
mice
review
quit
interestingli
studi
group
other
demonstr
increas
hepat
baselin
pretreat
express
level
subset
isg
includ
associ
treatment
nonrespons
type
ifnbas
therapi
hcv
hbv
patient
isg
classic
known
antivir
increas
isg
contribut
treatment
failur
remain
obscur
howev
reveal
isgyl
stimul
hcv
product
also
blunt
ifn
antihcv
activ
either
hcv
replicon
cell
cell
infect
hepat
c
viru
result
indic
hcv
exploit
host
immun
evas
mechan
facilit
replic
persist
studi
set
investig
effect
isgyl
hbv
replic
product
isgyl
express
level
modifi
overexpress
plasmid
sirna
target
result
indic
promot
hbv
product
depend
isgyl
studi
provid
novel
evid
hbv
exploit
host
innat
immun
facilit
persist
cultur
previous
describ
human
fulllength
gene
gener
use
plasmid
dna
mgc
clone
open
biosystem
templat
result
pcr
product
clone
topo
ta
express
vector
invitrogen
usa
sequenc
primer
forward
revers
respect
plasmid
maxiprep
kit
qiagen
german
use
prepar
plasmid
dna
transfect
cell
integr
fulllength
hbv
genom
kindli
provid
professor
bo
qin
chongq
medic
univers
china
previous
describ
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
usa
supplement
heatinactiv
fetal
bovin
serum
gibco
usa
iu
ml
penicillin
gibco
usa
iu
ml
streptomycin
gibco
usa
mg
ml
invitrogen
usa
co
c
twentyfour
hour
transfect
cell
seed
plate
cell
per
well
antibioticsfre
medium
transfect
complex
prepar
l
serumfre
medium
mix
g
unless
otherwis
indic
plasmid
dna
l
polyethyleneimin
pei
g
l
let
mixtur
stand
minut
room
temperatur
cell
wash
three
time
antibioticsfre
medium
transfect
mix
ad
well
contain
ml
antibioticsfre
medium
cultur
medium
chang
hour
later
two
day
follow
transfect
cell
medium
harvest
total
rna
prepar
use
trizol
invitrogen
usa
reversetranscript
carri
use
iscript
cdna
tabl
western
blot
process
describ
detail
previous
also
perform
confirm
protein
express
isgyl
hbv
product
quantif
cultur
supernat
dna
total
intracellular
rna
extract
use
qiaamp
dna
blood
mini
kit
qiagen
german
trizol
invitrogen
usa
accord
kit
manufactur
instruct
respect
realtim
pcr
carri
state
hbvspecif
primer
tabl
intracellular
coval
close
circular
dna
cccdna
extract
purifi
accord
previou
report
measur
realtim
pcr
describ
previous
supernat
hbsag
hbeag
detect
enzymelink
immunosorb
assay
elisa
kit
biosamit
shanghai
china
follow
manufactur
protocol
intracellular
hbcag
express
assess
western
blot
use
polyclon
antihbcag
antibodi
boster
biolog
technolog
wuhan
china
integr
densiti
calcul
use
imagej
softwar
differ
two
categor
valu
compar
student
ttest
statist
signific
set
experi
repeat
least
three
time
antivir
effect
mainli
attribut
form
isgyl
protein
ask
whether
conjug
increas
ectop
express
seen
figur
transfect
led
pronounc
increas
express
confirm
western
blot
figur
b
addit
unlik
hela
cell
isgyl
difficult
induc
overexpress
alon
increas
isgyl
figur
b
cell
express
significantli
affect
elev
isgyl
though
matur
form
conjug
target
protein
shown
essenti
antivir
effect
free
intracellular
extracellular
isgyl
could
detect
indic
potenti
function
free
involv
viral
infect
therebi
investig
whether
free
form
isgyl
respons
increas
hbv
product
sinc
catalyz
adenyl
inhibit
suppress
conjug
first
determin
effici
knockdown
realtim
pcr
shown
figur
mrna
express
significantli
inhibit
nm
nm
sirna
use
nm
sirna
follow
experi
knockdown
confirm
western
blot
figur
b
compar
nonknockdown
group
figur
b
lane
cell
show
lower
level
protein
figur
b
lane
respons
overexpress
although
level
free
experienc
appar
differ
ifn
treat
cell
includ
posit
control
show
express
isgyl
figur
b
lane
parallel
knockdown
consequ
downregul
isgyl
supernat
hbv
dna
return
baselin
level
figur
c
result
indic
stimul
hbv
product
isgylationdepend
manner
ask
whether
knockdown
could
inhibit
hbv
product
suppress
express
cell
without
overexpress
monitor
hbv
product
measur
intracellular
total
hbv
dna
pgrna
hbcag
well
hbv
dna
hbsag
hbeag
cultur
medium
interestingli
hbv
product
seem
affect
knockdown
see
supplementari
figur
figur
addit
hbv
product
cell
scarc
affect
shortperiod
h
ifn
treatment
unpublish
data
result
suggest
may
involv
hbv
product
independ
type
ifn
signal
pathway
although
exert
function
three
differ
form
includ
free
intracellular
conjug
extracellular
cytokin
isgyl
undoubtedli
import
one
abl
conjug
cellular
protein
mani
viral
protein
eg
influenza
viru
protein
human
papillomaviru
hpv
capsid
protein
directli
alter
function
modifi
protein
disrupt
ubiquitin
process
prevent
degrad
conjug
protein
studi
block
isgyl
abrog
increas
product
hbv
indic
isgyl
predomin
form
boost
hbv
product
cell
due
fact
also
check
antivir
effect
suppress
alon
without
overexpress
cell
unfortun
signific
antihbv
effect
observ
sinc
ifnstimul
gene
mainli
induc
ifn
stimul
baselin
although
propos
effici
host
defens
respons
variou
viral
infect
increas
evid
impli
antivir
mechan
may
virusspecif
may
exploit
virus
facilit
viral
replic
product
either
neg
regul
host
immun
directli
promot
viral
replic
blunt
ifn
antivir
activ
mani
respect
isgylationdeisgyl
process
resembl
ubiquitinationdeubiquitin
system
involv
physiolog
patholog
process
suggest
potenti
regul
activ
isgyl
biolog
especi
innat
immun
isgyl
protein
involv
ifn
signal
may
inhibit
signal
cascad
rna
helicas
enzym
retino
acid
induc
gene
rigi
pattern
recognit
receptor
prr
activ
viral
infect
result
endogen
type
ifn
express
kim
et
al
demonstr
isgyl
rigi
reduc
basal
virusinduc
ifn
promot
activ
cellular
level
neg
feedback
manner
jeon
et
al
found
isgyl
filamin
b
antagon
type
ifninduc
jun
ntermin
kinas
jnk
signal
pathway
filamin
b
act
scaffold
tether
cascad
member
type
ifn
activ
jnkspecif
signal
cascad
compos
jnk
conjug
filamin
b
lead
releas
scaffold
protein
interdict
signal
consequ
easi
understand
decreas
isgyl
result
increas
phenotyp
sensit
ifnin
sever
hepatoma
deriv
cell
line
even
nonhepat
cell
line
previou
work
also
indic
isgyl
promot
hcv
product
partli
decreas
antihcv
effect
ifn
therefor
explor
express
type
interferon
ifn
pathway
activ
cell
consist
previou
studi
demonstr
could
increas
phosphoryl
promot
type
ifn
signal
pathway
result
also
reveal
activ
type
ifn
signal
character
amplifi
express
isg
howev
signific
chang
ifn
ifn
express
observ
follow
overexpress
although
report
hbv
replic
significantli
suppress
cell
treatment
novel
livertarget
interferon
ifncsp
data
unpublish
show
hbv
product
cell
sensit
shortperiod
ifn
treatment
eg
h
treatment
indic
effect
transient
upregul
isgyl
hbv
product
might
independ
type
ifn
stabl
transfect
cell
may
employ
investig
effect
isgyl
type
ifn
signal
pathway
futur
studi
hand
consid
appar
antivir
role
surpris
mani
virus
develop
immun
evas
tactic
evolut
avoid
isgyl
either
inhibit
format
conjug
disrupt
form
modif
report
yuan
krug
influenza
b
viru
noncoval
bind
inhibit
interact
therebi
inhibit
isgyl
guerra
et
al
also
observ
vaccinia
viru
protein
bind
ctermin
domain
inhibit
conjug
virus
like
dugb
viru
dugv
sar
coronaviru
even
hydrolyz
target
protein
ovarian
tumor
domain
otu
contain
proteas
papainlik
proteas
moreov
present
studi
seem
hbv
evolv
make
use
isgyl
promot
product
indic
novel
mechan
hbv
persist
order
explor
detail
mechan
use
realtim
pcr
describ
test
express
level
sodium
taurochol
cotransport
polypeptid
ntcp
kda
glucoseregul
protein
identifi
essenti
factor
hbv
life
cycl
howev
none
gene
experienc
conspicu
chang
mrna
express
follow
overexpress
data
shown
therefor
hypothes
instead
regul
gene
express
isgyl
may
primarili
alter
function
stabil
cellular
viral
protein
involv
hbv
product
especi
hbv
secret
consid
unaffect
intracellular
pgrna
cccdna
total
hbv
dna
studi
reveal
complex
multipl
role
isgyl
work
need
determin
precis
mechan
therapi
target
pathway
target
develop
futur
interestingli
function
isgyl
viral
infect
seem
restrict
specif
host
kim
et
al
report
hbv
replic
affect
isgylationdefici
mice
construct
hbv
replic
model
inject
replicationcompet
dna
construct
hydrodynam
mice
although
signific
differ
conjug
knockout
mice
wild
mice
hbv
replic
affect
studi
influenza
b
viru
may
provid
implic
explain
differ
although
influenza
b
viru
protect
viru
isgyl
bind
human
primat
bind
mous
indic
speciesspecif
featur
conclus
current
studi
report
import
novel
role
isgyl
regul
hbv
life
cycl
cell
model
stabli
express
hbv
result
studi
provid
ration
explan
drug
especi
type
ifn
resist
persist
infect
hbv
make
possibl
predictor
tradit
ifn
therapi
potenti
antivir
target
hbv
treatment
